Brokers Issue Forecasts for VRTX Q1 Earnings
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Vertex ...
AFP1d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Given “Hold” Rating at Needham & Company LLC
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $467.00 Price Target at Barclays
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $520.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga ...
Royal Bank of Canada Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.
AFP3d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
LONDON Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited ...
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Vertex stock price target raised to $520 at Truist Securities
Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...
BMO maintains Vertex stock Outperform rating, $545 target
BMO Capital Markets maintained its Outperform rating and $545.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), representing a 16% upside from the current price of $469.97. With a ...
Morgan Stanley lifts Vertex stock price target to $459
Morgan Stanley (NYSE:MS) adjusted its outlook on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, raising the price target from the previous $450.00 to $459.00, while maintaining an ...